ArticleBMC infectious diseases2025
Validity of high-sensitivity C-reactive protein versus DAD equation for cardiovascular risk assessment in people living with HIV in Nigeria.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Predictive value of combined TyG-BMI and hsCRP for clinical outcomes in patients with chronic coronary syndrome undergoing PCI: a retrospective cohort study.BMC cardiovascular disorders · 2026Article
- Predictors of cardiovascular disease among people living with HIV in northern Nigeria.Research square · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundCardiovascular risk assessment is challenging in people living with HIV (PLWH). The aim of this study is to determine the validity of high-sensitivity C-reactive protein (hsCRP) compared to the Data-collection on Adverse effects of Anti-HIV Drugs (DAD) equation for cardiovascular risk prediction in PLWH in Nigeria.
methodsUsing a cross-sectional study design, we systematically recruited 180 HIV-positive adults attending a tertiary hospital in Kano, Nigeria. We estimated the 5-year projected CVD risk for each participant using both the DAD equation and hsCRP. The performance of hsCRP as a new tool was then compared to the DAD equation (reference tool) by evaluating sensitivity, specificity and area under the curve (AUC) to discriminate performance.
resultsThe mean age (± standard deviation) of the participants was 44.03 ± 10.58 years. The predictive accuracy of hsCRP for high CVD risk showed a specificity of 88.0%, sensitivity of 77.3%, and an AUC of 0.901 (95% confidence interval, CI: 0.824-0.978, p < 0.001) with hsCRP cut-off point for high risk set at > 3.03 mg/L. Comparison between the two models showed a moderate positive correlation (r = 0.58, p < 0.001) and fair agreement (κ = 0.26, p < 0.001). No factors significantly influenced the validity of hsCRP after regression modeling.
conclusionhsCRP is an excellent predictor of cardiovascular disease risk in PLWH, independent of traditional risk factors, comorbidities, and sociodemographic characteristics. Our findings suggest that hsCRP could be a feasible option for cardiovascular risk assessment in resource-limited settings, pending further validation in diverse populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.